InflammationPhase 1NCT02188407
Inflammation After One Lung Ventilation
A Phase 1 study testing Sevoflurane and Propofol in people with Inflammation, run by University Medical Centre Ljubljana at 1 site in Slovenia.
Trial summary
The aim of the study was to prospectively investigate the influence of one-lung ventilation (OLV) on the inflammatory response and to identify possible antiinflammatory effects of the volatile anaesthetic sevoflurane. Read more about this study
- Who is it for?
- Ages 20 to 70 years
- Conditions the study is for
- Inflammation
- What is being tested?
- Sevoflurane and Propofol
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteSlovenia
- Study dates
- Jul 2008to Jan 2014
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 20-70 years
- American Society of Anaesthesiologists (ASA) physical status I-III
- elective open lobectomy with OLV
Who cannot join
- history of drug hypersensitivity
- drug addiction
- treatment with psychotropic drugs
- severe psychiatric and central nerve system diseases
- persistent tobacco abuse, autoimmune system diseases
- diabetes mellitus
Show all 13Show fewer
- cardiac failure (New York Heart Association class greater than 2)
- clinically relevant obstructive and restrictive lung diseases (vital capacity or forced expiratory volume in 1s lover than 50% of the predicted values)
- pulmonary hypertension (mean pulmonary arterial pressure grater than 25 mmHg)
- pre-existing coagulation disorders
- history of treatment with immunosuppressant drugs in the 4 weeks before surgery
- Patient with evidence of pulmonary or systemic infections (C-reactive protein serum concentration greater than 5 mg/L, leucocytosis greater than 10.0 bioparticles/L or body temperature greater than 37 stC)
- perioperative blood derivatives, steroids or non-steroidal anti-inflammatory drug (NSAID)
Trial locations and contacts
1 site in 1 country.
Slovenia1 site
UMCLjubljana, CD of Anaesthesiology and Intensive Therapy
Ljubljana, 1230
About this study
Official title: Phase 1 Study of Antiinflammatory Effect of Sevoflurane in Open Lung Surgery With One-Lung Ventilation
The aim of the study was to prospectively investigate the influence of one-lung ventilation (OLV) on the inflammatory response and to identify possible antiinflammatory effects of the volatile anaesthetic sevoflurane.
Forty patients undergoing thoracic surgery with OLV were enrolled in this prospective, randomised study. The patients were randomly allocated into two groups to receive either propofol (Group P) or sevoflurane (Group S) for induction and maintenance of anaesthesia.
Read more
Inflammatory mediators (Interleukin 6 (IL6), Interleukin8 (IL8), Interleukin 10 (IL10), (C- reactive protein)CRP) were measured intra- and postoperatively.
Six hours after surgery oxygenation index (PaO2/FiO2) was calculated and chest X ray was taken and assessed.
The clinical outcome determinated by postoperative adverse events was assessed as the secondary endpoint.
Read the detailed description
Lung injury is the main complication of open lung surgery and is associated with a very high mortality rate.
In 1984, Zeldin reported on ten patients with a complication that he referred to as postpneumonectomy pulmonary oedema (PLE). The complication is sometimes not easy to differentiate from acute respiratory distress syndrome (ARDS), defined by Bernard et al, because the patients may not fulfill all the ARDS criteria. The incidence of this so-called acute lung injury (ALI) after lobectomy is 1-7%. The mortality rate in patients with ARDS and ALI is 72% and 33%, respectively.
In patients undergoing lung resection, mechanical ventilation and surgery may induce alveolar and systemic inflammatory responses. One-lung ventilation (OLV) has become as a standard procedure for many interventions in thoracic surgery with a need for deflation of the lung to facilitate the surgical procedure. It is also the main cause of acute inflammatory response and is associated with ALI and ARDS. The inflammatory reaction produces injury to the lung endothelium. The loss of endothelium integrity causes increased protein leak into the alveolar fluid. The inflammatory reaction leads to other histological changes. These reactions during OLV have been reported by many investigators.
A number of studies have shown that sevoflurane attenuates cardiac ischaemia-reperfusion injury. These results have been lately transferred to lung surgery. Some studies have demonstrated that volatile anaesthetics sevoflurane, isoflurane and desflurane have an impact on ischaemic-reperfusion lung injury. These studies have confirmed the local alveolar, but not the systemic antiinflammatory effects of sevoflurane.
Studies to date have not evaluated long-lasting effects of anaesthetics administered intraoperatively.
Demonstrating the influence of volatile anaesthetics on the inflammatory response and the treatment outcome in patients undergoing open lung surgery with OLV is still a great challenge for thoracic anaesthesiologists.
The effects of sevoflurane on release of inflammatory markers has been addressed before, but the added value of our study is that we tested the systemic imunomodulatory effect of sevoflurane in combination with postoperative clinical outcome and adverse effects.
In the current study the following null hypothesis was tested: the administration of sevoflurane or propofol does not affect the systemic proinflammatory response after open lung surgery with OLV.
ANAESTHESIA REGIMEN All patients were given oral diazepam 5-10 mg (Apaurin, Krka, d.d.) one hour before surgery. On arrival in the operating room, they were randomly assigned to either Group P or Group S. Randomisation was done according to computer-generated order.
Antibiotic prophylaxis with intravenous (iv) cefazolin (Cefamezin, Krka, d.d.) 2g/100 ml 0.9% NaCl was used in all patients.
Standardised clinical monitoring devices were attached to all patients prior to induction of anaesthesia. For extended haemodynamic monitoring LiDCO plus system was used.
A thoracic epidural catheter was inserted at the T6-7 level. Anaesthesia induction in Group P was performed with propofol (Propoven, Fresenius Kabi) and in Group S with sevoflurane (Sevorane, Abbott Laboratories). Before intubation all patients received remifentanil (Ultiva, GlaxoSmithKline) and vecuronium (Norcuron, Organon).
All patients were intubated with a left-sided double-lumen endobronchial tube (Malinckrodt, with hook, 37-41 Charriere) and ventilated by volume-controlled ventilation, provided by a closed-circuit anaesthesia ventilator (Primus, Draeger, Luebeck, Germany). The tidal volume was set to 6 ml/kg. The peak inspiratory pressure was limited to 25 cm H2O. The fraction of inspired oxygen was adjusted to maintain oxyhaemoglobin saturation at greater than 96% (fraction of inspired oxygen 0.3 to 0.4 before OLV; fraction of inspired oxygen 0.6 to 0.7 during OLV, and the respiratory rate to keep the PaCO2 between 3.8-4.5 kPa. The positive end expiratory pressure (PEEP) was set to 5 cm H2O. Gas concentration and airway pressures were measured at the proximal end of the tube using ventilator-integrated functions. During OLV the tidal volume was set to 4 ml/kg and peak inspiratory pressure limited to 25 cm H2O. Other ventilation settings were maintained and PEEP was reduced to 3 cm H2O.
Anaesthesia was maintained with propofol in Group P (4-6 mg/kg/h) and with sevoflurane (V% 2-2.5) in Group S. The rate of remifentanil iv infusion was 0.3-0.5 mcg/kg/min in both groups. The depth of anaesthesia was measured by a bispectral index (BIS) monitor; BIS values were maintained at 40-60.
For haemodynamic management the following algorithm was used: continuous infusion of 0.9% NaCl 6 mL /kg for the first hour, followed by 2.5 ml /kg/h, if DO2I<600 ml/min/m2 and SVR> 800 and SVV > 10% 6% hydroxyethyl starch (Voluven, Fresenius Kabi) until SVV decreased under 10% ; if there was no improvement after 250 ml 6% HES-a, dobutamine (Inotop Torrex Pharma) 1-10 mcg/kg/min iv is introduced; if SVR < 800 dyn•s/cm5 then ephedrine (0.5% Efedrin, UMC Ljubljana Pharmacy) 5-10 mg iv was given. If the mean arterial pressure increases by more than 30% and the heart rate by more than 30% from baseline, the infusion of remifentanil is increased by 0.1mcg/kg/min.
At the end of the procedure, the action of muscle relaxants was reversed with neostigmine (Neostigmin-Actavis, Actavis) 2.5 mg and atropine (Atropinum sulfuricum, Nycomed) 1 mg iv. All patients were extubated in the operating theatre and then transferred to the recovery room.
POSTOPERATIVE MANAGEMENT After surgery, the patients stayed in the recovery room for one hour and were then transferred to the intensive care unit of the Department of Thoracic Surgery.
Standard postoperative monitoring generally used in these procedures was implemented. Haemodynamic monitoring using the LiDCO plus system was continued after surgery.
Oxygen titrated to the lowest level needed to achieve the target arterial oxygen saturation of 96%, was administered via a Venturi mask.
For postoperative haemodynamic management the following algorithm was implemented: continuous infusion of 0.9% NaCl 1 ml/kg/h , if oxygen delivery index (DO2I) was less than 600 ml/min/m2 and systemic vascular resistance (SVR) was higher than 800 dyn•s/cm5 infusion of 6% hydroxyethyl starch (Voluven, Fresenius Kabi), if no improvement occurs after 250 ml 6% HES, dobutamine (Inotop, Torrex Pharma) 1-10 mcg/kg/min was initiated, if SVR < 800 than ephedrine (0.5% Efedrin, Pharmacy UMC Ljubjana ) 5-10 mg iv was given.
In the recovery room, all patients received 10 ml of 0.5% levo-bupivacaine (Chirocaine, Abbott Laboratories) and the level of the epidural sensory block was tested. Postoperative analgesia was provided by infusion of 0.25 % levobupivacaine via an epidural catheter using a patient- controlled analgesia (PCA) pump. The infusion rate was 5 ml/h and lockout time 30 min. Hourly pain assessments using a visual analogue scale (VAS) were performed. Patients with VAS scores greater than 3 received a rescue analgetic piritramide 3 mg (Dipidolor, Johnson\&Johnson) intravenously.
MEASUREMENTS The data recorded included demographic characteristics, time of surgery, time of OLV and DO2.
Arterial blood samples for the determinations of cytokines (IL 6, IL 8, IL 10), C-reactive protein (CRP) were drawn at the following time points: 1. before induction, 2. five minutes after the placement of the retractor, 3. 10 minutes after the beginning of OLV, 4. at the end of surgery, and 5. 6 hours after surgery. CRP was measured also 24 hours after the operation. For the analysis of serum CRP, IL 6, IL 8 and IL 10, blood samples were collected without additive. After centrifugation, serum samples were stored at -20 °C until analysis. Samples were analysed in one batch. CRP, IL 6, IL 8 and IL 10 were measured by a chemiluminescent immunometric assay (Immulite analyser; Simens Healthcare, Erlangen, Germany); a high-sensitivity method with a detection limit of 0.3 mg/L was used for measuring CRP.
Procalcitonin (PCT) levels were measured 6 and 24 hours after the operation. Chest X-rays were taken 6 hours after the procedure to evaluate the infiltration of the nonoperated lung. The following scoring was used: 0=no infiltration; 1=partly infiltrated; and 2= fully infiltratied.
The oxygenation index (ratio of partial arterial oxygen pressure to inspiratory fraction of oxygen =PaO2/FiO2) was calculated 6 hours after the procedure.
SECONDARY ENDPOINTS The clinical postoperative outcome was assessed as secondary endpoint based on adverse events. The following parameters were determined: prolonged antibiotics, diagnosed pneumonia, reintubation, systemic inflammatory response syndrome, sepsis, acute respiratory distress syndrome, acute renal failure, postoperative nausea and vomiting and death.
STATISTICAL ANALYSIS Statistical analysis were performed using the R software v 3 (R Development Core Team). All p-values reported are two-sided and the significance level was set at 5% (p < 0.05). Continuous variables are presented as mean ±SD.
Repeated measures ANOVA was used to identify differences in plasma CRP, IL6, IL8 and IL10 concentrations between the two study groups.
Based on authors' previous pilot study in 6 patients, to detect the significant difference of the IL 6 concentration with a significance level of 0.05 and a power of 80%, 16 patients in each group sufficed for the primary test. To compensate for withdrawals, 20 patients per group were included in the study.
Where appropriate t-test, Mann-Whitney tests and Chi-square test were also used.
- Conditions
- Inflammation
- Being tested
- Sevoflurane, Propofol
- Keywords
- thoracotomy, one-lung ventilation (OLV), total intravenous anaesthesia (TIVA), volatile induced and maintained anaesthesia (VIMA), cytokines, interleukine (IL)
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SevofluraneDrug
Also called Sevorane
MAC 3-5 V% during surgery
PropofolDrug
Propofol group (P group)- The group anaesthesied with propofol
| Study group | Role | What they receive |
|---|---|---|
| Sevoflurane | Experimental | Sevoflurane group (S group)- The group anaesthesied with sevoflurane Receives: Drug: Sevoflurane |
| Propofol | Active comparator | Propofol 4-6 mg/kg/h iv Receives: Drug: Propofol |
What is being measured
The primary outcome is the main question the study is designed to answer.
IL 6
IL 6 blood level (ng/L) at the 1. Insertion of the retractor, 2. Begining of OLV 3. End of surgery, 4. Six hours after surgery
Measured: intraoperatively and 6 hours after surgery
Secondary outcomes (5)
IL8
IL 8 (mg/L) blood level at the 1. Insertion of the retractor, 2. Begining of OLV 3. End of surgery, 4. Six hours after surgery
Measured: intraoperatively , 6 hours after surgery
IL10
IL 10 blood level (ng/L) at the 1. Insertion of the retractor, 2. Begining of OLV 3. End of surgery, 4. Six hours after surgery
Measured: intraoperatively , 6 hours after surgery
CRP
CRP blood level 24 hours after surgery
Measured: 24 hours after surgery
Oxygenation index
pO2/FiO2
Measured: 6h after surgery
Lung infiltration
X-ray of the lung- clear lungs, partly infiltrated lungs, totally infiltrated lungs
Measured: 6h after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2014 (estimated)
- Study startJul 2008
- Primary completionSep 2013
- Study completionJan 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for InflammationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Centre Ljubljana
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Iztok Potocnik, University Medical Centre Ljubljana
- Investigators
- Iztok Potocnik, MD, MSC, Principal investigator, University Medical Centre LjubljanaVesna Novak Jankovic, MD, PROF, Study chair, University Medical Centre Ljubljana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02188407
- Sponsor's protocol ID
- UKC-TOR-1
- Status last verified
- Jul 2014
- First submitted
- 3 Jul 2014
- Last updated
- 11 Jul 2014
- Results posted
- No
- Data monitoring committee
- Yes
Publications
De Conno E, Steurer MP, Wittlinger M, Zalunardo MP, Weder W, Schneiter D, Schimmer RC, Klaghofer R, Neff TA, Schmid ER, Spahn DR, Z'graggen BR, Urner M, Beck-Schimmer B. Anesthetic-induced improvement of the inflammatory response to one-lung ventilation. Anesthesiology. 2009 Jun;110(6):1316-26. doi: 10.1097/ALN.0b013e3181a10731.
PubMed 19417610Schilling T, Kozian A, Senturk M, Huth C, Reinhold A, Hedenstierna G, Hachenberg T. Effects of volatile and intravenous anesthesia on the alveolar and systemic inflammatory response in thoracic surgical patients. Anesthesiology. 2011 Jul;115(1):65-74. doi: 10.1097/ALN.0b013e318214b9de.
PubMed 21399490Schilling T, Kozian A, Kretzschmar M, Huth C, Welte T, Buhling F, Hedenstierna G, Hachenberg T. Effects of propofol and desflurane anaesthesia on the alveolar inflammatory response to one-lung ventilation. Br J Anaesth. 2007 Sep;99(3):368-75. doi: 10.1093/bja/aem184. Epub 2007 Jul 9.
PubMed 17621602Potocnik I, Novak Jankovic V, Sostaric M, Jerin A, Stupnik T, Skitek M, Markovic-Bozic J, Klokocovnik T. Antiinflammatory effect of sevoflurane in open lung surgery with one-lung ventilation. Croat Med J. 2014 Dec;55(6):628-37. doi: 10.3325/cmj.2014.55.628.
PubMed 25559834
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 1 Study of Antiinflammatory Effect of Sevoflurane in Open Lung Surgery With One-Lung Ventilation
- ClinicalTrials.gov ID
- NCT02188407
- Acronym / sponsor ID
- UKC-TOR-1
- Conditions
- Inflammation
- Keywords
- thoracotomy, one-lung ventilation (OLV), total intravenous anaesthesia (TIVA), volatile induced and maintained anaesthesia (VIMA), cytokines, interleukine (IL)
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University Medical Centre LjubljanaUniversity, hospital or other
- Study start
- Jul 2008
- Primary completion
- Sep 2013 (actual)
- Study completion
- Jan 2014 (actual)
- First posted
- 11 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study was to prospectively investigate the influence of one-lung ventilation (OLV) on the inflammatory response and to identify possible antiinflammatory effects of the volatile anaesthetic sevoflurane.
Forty patients undergoing thoracic surgery with OLV were enrolled in this prospective, randomised study. The patients were randomly allocated into two groups to receive either propofol (Group P) or sevoflurane (Group S) for induction and maintenance of anaesthesia.
Inflammatory mediators (Interleukin 6 (IL6), Interleukin8 (IL8), Interleukin 10 (IL10), (C- reactive protein)CRP) were measured intra- and postoperatively.
Six hours after surgery oxygenation index (PaO2/FiO2) was calculated and chest X ray was taken and assessed.
The clinical outcome determinated by postoperative adverse events was assessed as the secondary endpoint.
Detailed description
Lung injury is the main complication of open lung surgery and is associated with a very high mortality rate.
In 1984, Zeldin reported on ten patients with a complication that he referred to as postpneumonectomy pulmonary oedema (PLE). The complication is sometimes not easy to differentiate from acute respiratory distress syndrome (ARDS), defined by Bernard et al, because the patients may not fulfill all the ARDS criteria. The incidence of this so-called acute lung injury (ALI) after lobectomy is 1-7%. The mortality rate in patients with ARDS and ALI is 72% and 33%, respectively.
In patients undergoing lung resection, mechanical ventilation and surgery may induce alveolar and systemic inflammatory responses. One-lung ventilation (OLV) has become as a standard procedure for many interventions in thoracic surgery with a need for deflation of the lung to facilitate the surgical procedure. It is also the main cause of acute inflammatory response and is associated with ALI and ARDS. The inflammatory reaction produces injury to the lung endothelium. The loss of endothelium integrity causes increased protein leak into the alveolar fluid. The inflammatory reaction leads to other histological changes. These reactions during OLV have been reported by many investigators.
A number of studies have shown that sevoflurane attenuates cardiac ischaemia-reperfusion injury. These results have been lately transferred to lung surgery. Some studies have demonstrated that volatile anaesthetics sevoflurane, isoflurane and desflurane have an impact on ischaemic-reperfusion lung injury. These studies have confirmed the local alveolar, but not the systemic antiinflammatory effects of sevoflurane.
Studies to date have not evaluated long-lasting effects of anaesthetics administered intraoperatively.
Demonstrating the influence of volatile anaesthetics on the inflammatory response and the treatment outcome in patients undergoing open lung surgery with OLV is still a great challenge for thoracic anaesthesiologists.
The effects of sevoflurane on release of inflammatory markers has been addressed before, but the added value of our study is that we tested the systemic imunomodulatory effect of sevoflurane in combination with postoperative clinical outcome and adverse effects.
In the current study the following null hypothesis was tested: the administration of sevoflurane or propofol does not affect the systemic proinflammatory response after open lung surgery with OLV.
ANAESTHESIA REGIMEN All patients were given oral diazepam 5-10 mg (Apaurin, Krka, d.d.) one hour before surgery. On arrival in the operating room, they were randomly assigned to either Group P or Group S. Randomisation was done according to computer-generated order.
Antibiotic prophylaxis with intravenous (iv) cefazolin (Cefamezin, Krka, d.d.) 2g/100 ml 0.9% NaCl was used in all patients.
Standardised clinical monitoring devices were attached to all patients prior to induction of anaesthesia. For extended haemodynamic monitoring LiDCO plus system was used.
A thoracic epidural catheter was inserted at the T6-7 level. Anaesthesia induction in Group P was performed with propofol (Propoven, Fresenius Kabi) and in Group S with sevoflurane (Sevorane, Abbott Laboratories). Before intubation all patients received remifentanil (Ultiva, GlaxoSmithKline) and vecuronium (Norcuron, Organon).
All patients were intubated with a left-sided double-lumen endobronchial tube (Malinckrodt, with hook, 37-41 Charriere) and ventilated by volume-controlled ventilation, provided by a closed-circuit anaesthesia ventilator (Primus, Draeger, Luebeck, Germany). The tidal volume was set to 6 ml/kg. The peak inspiratory pressure was limited to 25 cm H2O. The fraction of inspired oxygen was adjusted to maintain oxyhaemoglobin saturation at greater than 96% (fraction of inspired oxygen 0.3 to 0.4 before OLV; fraction of inspired oxygen 0.6 to 0.7 during OLV, and the respiratory rate to keep the PaCO2 between 3.8-4.5 kPa. The positive end expiratory pressure (PEEP) was set to 5 cm H2O. Gas concentration and airway pressures were measured at the proximal end of the tube using ventilator-integrated functions. During OLV the tidal volume was set to 4 ml/kg and peak inspiratory pressure limited to 25 cm H2O. Other ventilation settings were maintained and PEEP was reduced to 3 cm H2O.
Anaesthesia was maintained with propofol in Group P (4-6 mg/kg/h) and with sevoflurane (V% 2-2.5) in Group S. The rate of remifentanil iv infusion was 0.3-0.5 mcg/kg/min in both groups. The depth of anaesthesia was measured by a bispectral index (BIS) monitor; BIS values were maintained at 40-60.
For haemodynamic management the following algorithm was used: continuous infusion of 0.9% NaCl 6 mL /kg for the first hour, followed by 2.5 ml /kg/h, if DO2I<600 ml/min/m2 and SVR> 800 and SVV > 10% 6% hydroxyethyl starch (Voluven, Fresenius Kabi) until SVV decreased under 10% ; if there was no improvement after 250 ml 6% HES-a, dobutamine (Inotop Torrex Pharma) 1-10 mcg/kg/min iv is introduced; if SVR < 800 dyn•s/cm5 then ephedrine (0.5% Efedrin, UMC Ljubljana Pharmacy) 5-10 mg iv was given. If the mean arterial pressure increases by more than 30% and the heart rate by more than 30% from baseline, the infusion of remifentanil is increased by 0.1mcg/kg/min.
At the end of the procedure, the action of muscle relaxants was reversed with neostigmine (Neostigmin-Actavis, Actavis) 2.5 mg and atropine (Atropinum sulfuricum, Nycomed) 1 mg iv. All patients were extubated in the operating theatre and then transferred to the recovery room.
POSTOPERATIVE MANAGEMENT After surgery, the patients stayed in the recovery room for one hour and were then transferred to the intensive care unit of the Department of Thoracic Surgery.
Standard postoperative monitoring generally used in these procedures was implemented. Haemodynamic monitoring using the LiDCO plus system was continued after surgery.
Oxygen titrated to the lowest level needed to achieve the target arterial oxygen saturation of 96%, was administered via a Venturi mask.
For postoperative haemodynamic management the following algorithm was implemented: continuous infusion of 0.9% NaCl 1 ml/kg/h , if oxygen delivery index (DO2I) was less than 600 ml/min/m2 and systemic vascular resistance (SVR) was higher than 800 dyn•s/cm5 infusion of 6% hydroxyethyl starch (Voluven, Fresenius Kabi), if no improvement occurs after 250 ml 6% HES, dobutamine (Inotop, Torrex Pharma) 1-10 mcg/kg/min was initiated, if SVR < 800 than ephedrine (0.5% Efedrin, Pharmacy UMC Ljubjana ) 5-10 mg iv was given.
In the recovery room, all patients received 10 ml of 0.5% levo-bupivacaine (Chirocaine, Abbott Laboratories) and the level of the epidural sensory block was tested. Postoperative analgesia was provided by infusion of 0.25 % levobupivacaine via an epidural catheter using a patient- controlled analgesia (PCA) pump. The infusion rate was 5 ml/h and lockout time 30 min. Hourly pain assessments using a visual analogue scale (VAS) were performed. Patients with VAS scores greater than 3 received a rescue analgetic piritramide 3 mg (Dipidolor, Johnson\&Johnson) intravenously.
MEASUREMENTS The data recorded included demographic characteristics, time of surgery, time of OLV and DO2.
Arterial blood samples for the determinations of cytokines (IL 6, IL 8, IL 10), C-reactive protein (CRP) were drawn at the following time points: 1. before induction, 2. five minutes after the placement of the retractor, 3. 10 minutes after the beginning of OLV, 4. at the end of surgery, and 5. 6 hours after surgery. CRP was measured also 24 hours after the operation. For the analysis of serum CRP, IL 6, IL 8 and IL 10, blood samples were collected without additive. After centrifugation, serum samples were stored at -20 °C until analysis. Samples were analysed in one batch. CRP, IL 6, IL 8 and IL 10 were measured by a chemiluminescent immunometric assay (Immulite analyser; Simens Healthcare, Erlangen, Germany); a high-sensitivity method with a detection limit of 0.3 mg/L was used for measuring CRP.
Procalcitonin (PCT) levels were measured 6 and 24 hours after the operation. Chest X-rays were taken 6 hours after the procedure to evaluate the infiltration of the nonoperated lung. The following scoring was used: 0=no infiltration; 1=partly infiltrated; and 2= fully infiltratied.
The oxygenation index (ratio of partial arterial oxygen pressure to inspiratory fraction of oxygen =PaO2/FiO2) was calculated 6 hours after the procedure.
SECONDARY ENDPOINTS The clinical postoperative outcome was assessed as secondary endpoint based on adverse events. The following parameters were determined: prolonged antibiotics, diagnosed pneumonia, reintubation, systemic inflammatory response syndrome, sepsis, acute respiratory distress syndrome, acute renal failure, postoperative nausea and vomiting and death.
STATISTICAL ANALYSIS Statistical analysis were performed using the R software v 3 (R Development Core Team). All p-values reported are two-sided and the significance level was set at 5% (p < 0.05). Continuous variables are presented as mean ±SD.
Repeated measures ANOVA was used to identify differences in plasma CRP, IL6, IL8 and IL10 concentrations between the two study groups.
Based on authors' previous pilot study in 6 patients, to detect the significant difference of the IL 6 concentration with a significance level of 0.05 and a power of 80%, 16 patients in each group sufficed for the primary test. To compensate for withdrawals, 20 patients per group were included in the study.
Where appropriate t-test, Mann-Whitney tests and Chi-square test were also used.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sevoflurane | Experimental | Drug: SevofluraneSevoflurane group (S group)- The group anaesthesied with sevoflurane |
| Propofol | Active comparator | Drug: PropofolPropofol 4-6 mg/kg/h iv |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients aged 20-70 years
- American Society of Anaesthesiologists (ASA) physical status I-III
- elective open lobectomy with OLV
Key exclusion criteria (13 listed)
- history of drug hypersensitivity
- drug addiction
- treatment with psychotropic drugs
- severe psychiatric and central nerve system diseases
- persistent tobacco abuse, autoimmune system diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SevofluraneAlso: SevoraneMAC 3-5 V% during surgery | Drug | Sevoflurane |
| PropofolPropofol group (P group)- The group anaesthesied with propofol | Drug | Propofol |
Primary outcome
IL 6
Time frame: intraoperatively and 6 hours after surgery
IL 6 blood level (ng/L) at the 1. Insertion of the retractor, 2. Begining of OLV 3. End of surgery, 4. Six hours after surgery
5 secondary outcomes
IL8
Time frame: intraoperatively , 6 hours after surgery
IL10
Time frame: intraoperatively , 6 hours after surgery
CRP
Time frame: 24 hours after surgery
Oxygenation index
Time frame: 6h after surgery
Lung infiltration
Time frame: 6h after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2014.
- Results publication: PubMed 19417610De Conno E, Steurer MP, Wittlinger M, Zalunardo MP, Weder W, Schneiter D, Schimmer RC, Klaghofer R, Neff TA, Schmid ER, Spahn DR, Z'graggen BR, Urner M, Beck-Schimmer B. Anesthetic-induced improvement of the inflammatory response to one-lung ventilation. Anesthesiology. 2009 Jun;110(6):1316-26. doi: 10.1097/ALN.0b013e3181a10731.
- Results publication: PubMed 21399490Schilling T, Kozian A, Senturk M, Huth C, Reinhold A, Hedenstierna G, Hachenberg T. Effects of volatile and intravenous anesthesia on the alveolar and systemic inflammatory response in thoracic surgical patients. Anesthesiology. 2011 Jul;115(1):65-74. doi: 10.1097/ALN.0b013e318214b9de.
- Results publication: PubMed 17621602Schilling T, Kozian A, Kretzschmar M, Huth C, Welte T, Buhling F, Hedenstierna G, Hachenberg T. Effects of propofol and desflurane anaesthesia on the alveolar inflammatory response to one-lung ventilation. Br J Anaesth. 2007 Sep;99(3):368-75. doi: 10.1093/bja/aem184. Epub 2007 Jul 9.
- Derived from this study: PubMed 25559834Potocnik I, Novak Jankovic V, Sostaric M, Jerin A, Stupnik T, Skitek M, Markovic-Bozic J, Klokocovnik T. Antiinflammatory effect of sevoflurane in open lung surgery with one-lung ventilation. Croat Med J. 2014 Dec;55(6):628-37. doi: 10.3325/cmj.2014.55.628.
Related trials for Inflammation
Not yet recruiting
TearCare in Young Adults
Meibomian Gland Dysfunction (Disorder)
Not yet recruiting
Investigation of the Gut-Brain Axis in Alcohol Use Disorder
Alcohol Use Disorder (AUD), Alcohol Abstinence
RecruitingPhase 2
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Microvascular Inflammation
RecruitingObservational study
Natural History of the Human Biological Response to Environmental Exposure and Injury
Inflammation, Normal Controls
Enrolling by invitationObservational study
Investigating Novel Strategies in Pediatric Immune Responses and Microbiome Environment: Comprehensive Lung Disease Investigation in Children.
Lung Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Iztok Potocnik, MD, MSC principal investigator
University Medical Centre Ljubljana
Vesna Novak Jankovic, MD, PROF study chair
University Medical Centre Ljubljana
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Sevoflurane and Propofol in people with Inflammation, run by University Medical Centre Ljubljana at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
IL 6 (time frame: intraoperatively and 6 hours after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02188407, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2014.